Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-06-04 00:00:00 ET · period of report 2024-05-31 · accession 0001714899-24-000140 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-04 | 2024-05-31 | DNLI | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +5,967 | 1.88M | +0.3% | $0 |
| D | 2024-06-04 | 2024-05-31 | DNLI | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +17.9K | 17.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-31 | A | A | 5,967 | $0.00 | 1,880,539 | D | — | — | (F1) Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. (F2) Includes 5,967 unvested RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2024-05-31 | A | A | 17,901 | $0.00 | 17,901 | D | $18.56 · — to 2034-05-31 | 17,901 Common Stock | (F6) 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |